Story
Scribe Therapeutics Closes $155.5 Million IPO, Secures Sanofi Private Placement
Summary
Clinical-stage biotechnology firm Scribe Therapeutics has completed its initial public offering, raising approximately $155.51 million in gross proceeds. The company also finalized a concurrent private placement with pharmaceutical major Sanofi.
Scribe Therapeutics Inc. (Nasdaq: SCTX) has successfully closed its initial public offering, raising aggregate gross proceeds of approximately $155.51 million before underwriting discounts and commissions. The offering's completion marks a significant capital infusion for the clinical-stage biotechnology company as it advances its development pipeline.
Offering Details
The Alameda, California-based company sold a total of 9,867,000 shares of its common stock at an IPO price of $15.00 per share. This figure includes 1,287,000 additional shares sold after the underwriters fully exercised their option to purchase more, according to a company press release.
The offering was managed by a syndicate of banks, with Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, and Wells Fargo Securities acting as joint book-running managers. The company's registration statement was declared effective by the U.S. Securities and Exchange Commission on July 23, 2026.
Concurrent Sanofi Investment
AdAlongside the public offering, Scribe Therapeutics also closed a concurrent private placement with the pharmaceutical company Sanofi. Sanofi purchased 500,000 shares of common stock at the IPO price of $15.00 per share.
These shares were not registered under the Securities Act of 1933 and are therefore subject to different regulations than those sold in the public offering. This separate transaction underscores existing investor interest from established industry players.
Market Debut
Shares of Scribe Therapeutics began trading on the Nasdaq Global Market on July 24, 2026, under the ticker symbol SCTX. The initial public offering officially closed on July 27, 2026, finalizing the process and securing the new capital for the company's operations.
Read next
More on Stocks
Northern Star Rejects Takeover Overture From Gold Fields, Bloomberg Reports
South Africa's Gold Fields Ltd. recently approached Australia's Northern Star Resources about a potential acquisition, but the offer was rejected, according to a report. The move comes as Northern Star faces pressure from an activist investor and deals with operational challenges.
European Telecoms Face AI-Driven Price Pressure, Bank of America Warns
Bank of America analysts report that while AI agents could increase customer churn for European telecom operators by simplifying price comparisons, the technology also offers powerful tools for sales and personalized customer retention.
ShinyHunters Hackers Renew Attacks on Oracle PeopleSoft Flaw, Google's Mandiant Reports
Google's cybersecurity unit, Mandiant, reports that the hacking group ShinyHunters has resumed and adapted its exploitation of a known vulnerability in Oracle's PeopleSoft enterprise software, targeting organizations that failed to apply a full security patch.
Manulife Stock Climbs, Supported by Cross-Border Investor Optimism
Shares of Manulife Financial gained on Tuesday, buoyed by a strong performance in U.S. markets rather than any specific company news. The stock's move is also supported by a bullish technical posture and positive analyst ratings.